



**Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings of claims in the application:

1-2. (Cancelled)

3. (Amended) The Δ glucagon-like peptide-1 receptor agonist according to the claim 1, wherein having the following structural formula:




wherein each of R<sub>5</sub> is alkyl; and R<sub>6</sub> independently is any one of the following substituent groups: alkyl; substituted alkyl which contains the substituent groups including halogen, alkoxy or hydroxyl; C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>3</sub>-C<sub>6</sub> cycloalkyl; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxy or hydroxyl; C<sub>2</sub>-C<sub>6</sub> enoyl; C<sub>3</sub>-C<sub>6</sub> cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxy and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoxyl; and mandeloyl; and X<sub>1</sub> is O or NH; X<sub>2</sub> is O or NH,



wherein  $R_2$  is any one of the following substituent groups: alkanoyl; substituted alkanoyl which contains substituent groups including halogen, alkoxy or hydroxyl;  $C_2$ - $C_6$  enoyl;  $C_3$ - $C_6$  cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxy and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoxyl; and mandeloyl; and  $X_2$  is O or NH;

X is O; and

Y is O



— wherein each of  $R_3$  and  $R_4$  independently is any one of the following substituent groups: alkyl; substituted alkyl which contains substituent groups including halogen, alkoxy or hydroxyl;  $C_2$ - $C_6$  alkenyl;  $C_3$ - $C_6$  cycloalkyl; alkanoyl; substituted alkanoyl which contains the substituent groups including halogen, alkoxy or hydroxyl;  $C_2$ - $C_6$  enoyl;  $C_3$ - $C_6$  cycloalkanoyl; benzoyl; substituted benzoyl which contains optional one, two or three substituent groups including alkoxy and alkylamino; tert-butoxycarbonyl; thenoyl; adamantane formoxyl; and mandeloyl; and  $X_1$  is O or NH;  $X_2$  is O or NH.

4-8. (Cancelled)

9. (Amended) Use of the glucagon-like peptide-1 receptor agonist according to claim 1 claim 3 in the preparation of as medicaments for treating the carbohydrate metabolism disturbance-related diseases such as including type II diabetes, insensitivity to insulin or obesity; etc.

10. (Cancelled)

11. (Amended) The glucagon-like peptide-1 receptor agonist according to the ~~claim 1~~ claim 3 having the following structural formula:

